JAK2 and acute lymphoblastic leukemia: This alteration did not increase the level of pulled-down RAS-GTP (Fig. 1a) and neither did the stable overexpression of hJAK2R683G [24], the most prevalent specific activating JAK2 mutation in DS-ALL and Ph-like-ALL.